Raymond James Financial Inc. Acquires New Stake in Envista Holdings Co. (NYSE:NVST)

Raymond James Financial Inc. acquired a new position in shares of Envista Holdings Co. (NYSE:NVST - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 560,265 shares of the company's stock, valued at approximately $10,808,000. Raymond James Financial Inc. owned 0.33% of Envista at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in shares of Envista by 22.2% in the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock valued at $69,749,000 after purchasing an additional 642,401 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Envista during the fourth quarter worth approximately $53,000. Lecap Asset Management Ltd. purchased a new stake in shares of Envista during the fourth quarter worth $281,000. Hotchkis & Wiley Capital Management LLC acquired a new stake in Envista in the 3rd quarter valued at about $14,965,000. Finally, Geode Capital Management LLC lifted its position in Envista by 2.5% during the third quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company's stock worth $57,233,000 after buying an additional 71,435 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NVST. Piper Sandler raised their price objective on shares of Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, February 3rd. Morgan Stanley lowered their price objective on Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. New Street Research set a $19.00 price target on Envista in a research note on Thursday, March 6th. Wells Fargo & Company set a $19.00 price objective on Envista in a research report on Saturday, March 8th. Finally, Mizuho initiated coverage on shares of Envista in a research report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 target price on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Envista has a consensus rating of "Hold" and an average price target of $20.18.

Remove Ads

Envista Stock Up 5.1 %

NVST traded up $0.85 on Monday, hitting $17.51. 2,621,033 shares of the company were exchanged, compared to its average volume of 2,328,581. The firm has a 50-day moving average price of $19.76 and a two-hundred day moving average price of $19.61. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $23.00. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -2.70, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities analysts predict that Envista Holdings Co. will post 1 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.